Break into the Boardroom
Break into the Boardroom is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Break into the Boardroom.
Break into the Boardroom is a company.
Key people at Break into the Boardroom.
Key people at Break into the Boardroom.
Break Into the Boardroom (BiB) is a nonprofit initiative founded in 2015 that connects high-performing female executives with board positions in leading healthcare organizations to drive greater impact, better outcomes, and gender diversity.[1][2] It cultivates women leaders by enhancing their governance knowledge and matching them to public, private, and non-profit boards, having placed over 375 women in 150+ new roles across 10 years, amid evidence that diverse boards outperform peers.[1][3][5] Today, BiB operates as an umbrella brand supporting expanded successor initiatives backed by its founders, focusing on healthcare transformation through bold female leadership.[1][2]
BiB was launched in 2015 (with formal collaboration starting in 2016) by Deerfield Management, a healthcare investment firm, and Oxeon Holdings, a healthcare growth services firm encompassing executive search, investments, and ventures.[2][3] Deerfield and Oxeon recognized that while talented female executives abound, the challenge lies in connecting them to board opportunities beyond existing networks, grounded in the belief that diverse boards transform healthcare.[2][3] Key figures include Deerfield Partner Leslie Henshaw, who highlighted the program's business rationale, and Oxeon leaders driving its practical, measurable approach.[3] Over a decade, BiB evolved from targeted placements—filling over 50 seats by 2022—to a community mentoring future generations, with alumni like June Lee M.D. crediting it for board seats at firms like CinCor Pharma and Tenaya Therapeutics.[1][3]
BiB rides the wave of boardroom diversity mandates and performance data showing gender-balanced boards excel in key metrics, amplified by healthcare's shift toward innovative, patient-centric models needing fresh perspectives.[1][3] Timing aligns with post-2020 regulatory pressures (e.g., SEC disclosures, investor demands) and healthcare's digital transformation, where women leaders bring underrepresented insights to biotech, pharma, and healthtech boards.[3][5] Market forces like talent shortages and ESG investing favor BiB, influencing the ecosystem by normalizing diverse governance—evidenced by placements at orgs like Cosette Pharmaceuticals, UNICEF, and Apollo Global Management—and inspiring similar programs.[5] It humanizes healthcare leadership, countering homogeneity in decision-making amid AI-driven drug discovery and telehealth booms.
BiB's momentum positions it to scale successor initiatives, potentially doubling placements as diversity becomes table stakes in healthcare governance.[1][2] Trends like AI ethics, personalized medicine, and global health equity will demand even more diverse boards, where BiB's alumni network can lead; expect deeper ties to healthtech unicorns and international expansion.[3][5] Its influence may evolve from connector to ecosystem shaper, mentoring the next cohort amid tightening talent wars—reinforcing that breaking into the boardroom isn't just equitable, it's essential for transformative healthcare impact.[1][4]
